Non-pancreatic hyperlipasemia: A puzzling clinical entity

Table 1 Demographic, clinical and laboratory characteristics at enrolment and outcome data of the acute pancreatitis and non-pancreatic hyperlipasemia patients, n (%)

	AP (n = 392)	NPHL (n = 401)	P value
Gender (male)	188 (48)	221 (55.1)	0.047
Age (yr)	62 (47-73)	66 (57-76)	< 0.001
Comorbidities any	310 (79)	369 (92)	< 0.001
CCI	3 (1-5)	5 (3-8)	< 0.001
Sepsis (yes)	56 (14.3)	111 (27.7)	< 0.001
Acute kidney injury (yes)	41 (10.5)	133 (33.2)	< 0.001
Sepsis and AKI (yes)	20 (5.1)	82 (20.4)	< 0.001
Lipase level (U/L)	1331 (579-2837)	278 (236-485)	< 0.001
Amylase level (U/L)	424 (172-1038)	170 (97-249)	< 0.001
Sodium (mmol/L)	139 (136-141)	139 (136-142)	0.568
Albumin (g/L)	39 (33-44)	35 (29-41)	< 0.001
BUN (mmol/L)	5.3 (3.7-7.8)	8.4 (5-20.35)	< 0.001
Creatinine (μmol/L)	73 (60-94)	92 (63-217)	< 0.001
GFR (mL/p/1.73m2)	87 (61-91)	61 (24-91)	< 0.001
WBC (G/L)	10.79 (7.81-14.45)	10.39 (7.63-14.61)	0.805
Neutrophil granulocyte (G/L)	8.46 (5.49-11.97)	7.87 (5.20-11.83)	0.584
Lymphocyte (G/L)	1.27 (0.83-1.82)	1.29 (0.82-1.89)	0.008
NLR	6.52 (3.54-12.93)	6.03 (3.21-12.40)	< 0.001
CRP (mg/L)	19.5 (5.8-95.34)	36.85 (10.88-101.93)	0.008
PCT (μg/L)	0.24 (0.09-0.69)	0.76 (0.25-3.13)	< 0.001
Total length of hospitalization (d)	7 (4-12)	8 (3-18)	0.126
ICU (yes)	174 (44.4)	182 (45.4)	0.830
ICU stay (d)	4 (2-7)	7 (3-16)	< 0.001
In-hospital mortality	20 (5.1)	90 (22.4)	< 0.001

Data are presented as median (interquartile range) if not otherwise indicated. For procalcitonin, the number of patients was 274 in non-pancreatic hyperlipasemia group and 238 in acute pancreatitis group. AP: Acute pancreatitis; NPHL: Non-pancreatic hyperlipasemia; IQR: Interquartile range; BUN: Blood urea nitrogen; GFR: Glomerular filtration rate; WBC: White blood cell; NLR: Neutrophil-to-lymphocyte ratio; CRP: C-reactive protein; PCT: Procalcitonin; ICU: Intensive care unit; CCI: Charlson Comorbidity Index; AKI: Acute kidney injury.